Share

Latest Research, Industry, Medical and Scientific News

product approval

URO-1’s Repris System for Injecting Botox Into Bladder

URO-1, based in Winston-Salem, North Carolina, got FDA approval for its Repris Bladder Injection System. The product is designed for delivering Botox injections into the bladder as a treatment option for overactive bladder. The device, which is supposed to make such procedures easier on the physicians and more comfortable on the patients, will be unveiled at the American Urological Association in San Francisco later this month. Read more.

Source: Medgadget, May 9, 20218

PeriCoach from Analytica

Analytica Expands Clinical Indication for Its Unique Pelvic Floor Exercise Technology

Analytica Limited (ASX:ALT) has received clearance from the Australian Therapeutic Goods Administration for the expanded clinical indication for its PeriCoach System to assist in the conservative treatment of Pelvic Organ Prolapse (POP).  The PeriCoach system with its patent protected force sensing technology assists women to properly perform pelvic floor exercises.  The expanded clinical indication for PeriCoach now includes targeted resolution of symptoms for mild to moderate POP, urinary incontinence and sexual wellness.  Data suggests that 50% of women that have given birth have some degree of POP and half of women over 50 complain of prolapse symptoms. Estimates state women have a lifetime risk of up to 12% of undergoing a surgical intervention, with a re-operation rate of nearly 20%. Read more.

Source: Proactiveinvestors Australia, May 2, 2018

product approval

FDA Approves Myrbetriq Combo Treatment for Overactive Bladder

The Food and Drug Administration (FDA) has approved Myrbetriq (mirabegron extended-release tablets; Astellas) in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. In clinical trials, the combination of Myrbetriq + solifenacin succinate was associated with greater improvements in the number of incontinence episodes per 24 hours (primary endpoint), the number of micturitions per 24 hours (primary endpoint), and the volume voided per micturition (secondary endpoint) compared to placebo or to individual active components. Long-term data also demonstrated that the effects of combination treatment were maintained throughout a 1-year treatment period. Read more.

Source: MPR, April 30, 2018

business buildings

Essity Partners with Plug and Play to Drive New Innovation in Hygiene

Essity, one of the world’s leading hygiene and health companies, announced that it will expand its partnership with Silicon Valley’s Plug and Play.  Plug and Play is the world’s leading startup accelerator and open innovation platform that connects startup companies with corporations for business development and investment opportunities. Essity joined Plug and Play’s Health & Wellness innovation platform last year to gain access to the company’s global ecosystem of startups, focusing on technologies that would strengthen Essity’s feminine care and baby care products. The relationship has now expanded to include professional hygiene and incontinence products. Read more.

Source: Market Insiders, April 27, 2018

drugs for overactive bladder (OAB)

Certain Common Medications Tied to 30% Higher Dementia Risk, Study Finds

Many older adults know that long-term use of certain medications can negatively affect cognition and increase one’s risk of dementia.  But a new study suggests that some classes of anticholinergic drugs — particularly those used to treat depression, Parkinson’s and urinary incontinence — carry a higher risk than others.  Anticholinergic drugs function by blocking the effects of acetylcholine, a chemical released by nerve cells to send signals to other nerves and muscles. They are prescribed to 20% to 50% of older adults in the United States to treat a variety of neurological, psychiatric, gastrointestinal, respiratory and muscular conditions, according to a 2009 study. In the UK, 34% to 48% of older adults take them, another study found.  Read more.

Source: CNN, April 25, 2018

business buildings

Restech acquires Mederi Medical

Medtech developer Respiratory Technology Corp said today it acquired Mederi Therapeutics, and its Stretta catheter and Secca system, for an undisclosed amount.  Houston-based Restech said that the addition of the Stretta catheter, designed to treat gastroesophageal reflux disease, and the Secca system, designed to treat bowel incontinence, are complimentary to its existing diagnostic devices.  Mederi’s Stretta catheter system is designed to apply low-power radio frequency energy to remodel the lower esophageal sphincter to restore natural barrier function and reduce spontaneous regurgitation caused by transient relaxations of the sphincter.  The Secca device uses a low-power radiofrequency generator to remodel the muscle of the internal anal sphincter to treat bowel incontinence, the company said.  Read more.

Source: Mass Device, April 26, 2018